Drug Database
CE

cetuximab (Lupitux / Cetuxa / ENZ124)

✓ Approved

Lupin Limited · EGFR · 单克隆抗体

什么是 cetuximab?

cetuximab 是一种单克隆抗体,由Lupin Limited研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intravenous (IV)。

药物档案

商品名Lupitux, Cetuxa, ENZ124
公司Lupin Limited
药物类别单克隆抗体, 抗体
分子靶点EGFR
给药途径Injectable (Others), Intravenous (IV)
状态Approved

作用机制

分子靶点

cetuximab 作用于 1 个分子靶点:

EGFRepidermal growth factor receptor (ERBB1, NNCIS)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

cetuximab 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Head and neck cancer metastatic✓ Approved

相关研究文献

PubMedJournal of the American Chemical Society2026-11-19

Receptor-Guided Targeted Protein Degradation Collapses Extracellular Vesicle-Driven Tumor-Stroma Crosstalk.

Kim Eun Hye EH, Park Byeongmin B, Kim Kyungsu K, Ryu Youngri Y et al.

Extracellular vesicles (EVs) are critical mediators of tumor-stromal communication within the tumor microenvironment (TME), where reciprocal signaling between cancer cells and cancer-associated fibroblasts (CAFs) fuels malignant progression and therapeutic resistance. Here, we report a degrader-antibody conjugate (DAC) platform, Ctx-ETAC, in which the clinically approved anti-EGFR antibody cetuximab (Ctx) delivers an engineered proteolysis-targeting chimera (PROTAC) payload, ETAC, selectively into EGFR-expressing tumor cells and activated CAFs via receptor-mediated endocytosis. ETAC integrates indomethacin as the COX-2 ligand, a VHL-recruiting peptide, and a cathepsin B (Cat-B)-cleavable azidoacetyl-RR linker; conjugation to Ctx was achieved by a two-step bioorthogonal strategy, yielding an average drug-to-antibody ratio of 4.21. The resulting Ctx-ETAC ensures biomarker-selective payload activation in both tumor cells and activated CAFs, markedly reducing EV secretion by 95.5% and thereby disrupting their crosstalk. This disruption of EV-mediated communication reprograms CAFs toward a quiescent phenotype and reshapes the non-small cell lung cancer microenvironment into an antitumor state. In a xenograft model, Ctx-ETAC achieves markedly superior tumor suppression compared with Ctx monotherapy, without systemic toxicity. These findings establish receptor-guided targeted protein degradation as a strategy to disrupt EV-driven tumor-stromal communication and provide a new framework for microenvironment-directed cancer therapy.

PMID 43053353
阅读全文 →
PubMedPathology oncology research : POR2026-11-18

A retrospective analysis of cetuximab efficacy based on the comprehensive RAS/RAF mutation profiles of colorectal cancer.

Tímár József J, Rásó Erzsébet E, Barbai Tamás T, Baranyi Marcell M et al.

In colorectal cancer the most frequently analyzed markers are RAS/RAF mutations which have negative predictive role for anti-EGFR antibody therapy. Although the hotspot mutations of the K- and NRAS exon 2-4 are well defined, the predictive role of rare mutations of other codons are questionable and the current guidelines are less precise in this respect. We have retrospectively re-analyzed the full spectrum of RAS/RAF mutations by next-generation sequencing (NGS) in a small cohort of nineteen cetuximab treated metastatic colorectal cancer patients whose enrollment was based on KRAS exon 2 mutation analysis. We have detected 13 rare RAS/RAF mutations where 5 occurred together with hotspot (HSP) mutations. In the five non-HSP mutant cases we have detected 8 rare/non-HSP RAS/RAF mutations: KRAS-E37.,C51Y, NRAS-D57N,E62K,G60E/V14I, HRAS-P34L and BRAF-G464R. Kaplan-Meier analysis indicated that the progression free survival (PFS) of non-HSP cases ran parallel with wild type (WT) cases separately from the HSP mutant cases without statistical significance (p = 0.156). However, the combination of WT group with non-HSP cases resulted in a near significant survival difference from HSP cases (p = 0.057, HR = 3.501). Kaplan-Meier analysis of the overall survival (OS) again demonstrated that the survival curve of WT cases ran parallel with non-HSP cases, clearly separated from the HSP cases (p = 0.024). Overall survival of WT cases was significantly different as compared to HSP cases (p = 0.005) with HR of 6.362 (CI 1.496-27.055) as expected, while it was not statistically different from non-HSP cases (p = 0.092) with a HR of 0.891 (CI 0.248-3.205). In this small retrospective study we showed that the analyzed non-HSP mutations of RAS/RAF in colorectal cancer treated with cetuximab do not have negative effect on the efficacy. Since our cohort is very small and do not have accordingly the necessary statistical power of the survival analyses, therefore can only be considered as hypothesis generating one of the issue of the predictive role of non-hotspot RAS mutations on cetuximab efficacy.

PMID 43047554
阅读全文 →
PubMedBioconjugate chemistry2026-11-18

SuFEx-Enabled Tyrosine Specific Bioconjugation of Near-Infrared Fluorophores.

McKay Paula T PT, Nashawati Stefan S, Kodisana Mohan M, Aden Jude E JE et al.

Sulfur (VI) fluoride exchange (SuFEx) chemistry has been widely applied in small-molecule medicinal chemistry, but its translation to near-infrared (NIR) fluorophores and application to antibody labeling remain largely unexplored. Here, we report a general synthetic approach for the preparation of aryl sulfonyl fluoride-functionalized indolenines and their incorporation into heptamethine cyanine (Cy7) fluorophores. The strategy is compatible with a broad range of indolenine substrates bearing diverse electronic and solubilizing substituents, enabling the synthesis of a library of water-soluble, SuFEx-enabled Cy7 fluorophores. Using SAT-NIR-746-SF as a lead probe, we demonstrate that the aryl sulfonyl fluoride handle is stable under physiologically relevant conditions (t1/2 > 18 h at pH 7.4) and enables efficient antibody labeling (degree of labeling up to 6.1) under mild aqueous conditions. The degree of labeling can be systematically controlled by varying reaction pH, incubation time, and reagent stoichiometry. The strategy was successfully applied to therapeutic monoclonal antibodies, including trastuzumab, panitumumab, and cetuximab, and the resulting conjugates were stable under acidic, physiological, and serum conditions. Amino acid selectivity assays and tandem mass spectrometry-based proteomics of labeled trastuzumab confirmed modification exclusively at tyrosine residues, establishing the tyrosine-selective nature of this conjugation platform. SAT-NIR-746-SF-conjugated secondary antibodies provided specific labeling of phospho-histone H3 (H3S10P) in confocal immunofluorescence microscopy. These results establish SuFEx-enabled Cy7 fluorophores as a practical platform for tyrosine-selective antibody bioconjugation and demonstrate their utility in fluorescence imaging applications.

PMID 43046850
阅读全文 →
PubMedClinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology2026-11-18

The CD1d-iNKT Axis Modulates Allergic Responses to Alpha-Gal.

Wang Yinghui Y, Rival Claudia M CM, Zhang Yugen Y, Vasan Soorya S et al.

Amblyomma americanum (Aa or lone star tick) bites can induce alpha-gal syndrome (AGS)-allergic responses to mammal products linked to galactose-alpha-1,3-galactose (alpha-gal or α-Gal)-specific (s)IgE. Peripheral blood mononuclear cells in AGS show increased CD4+T cell-associated gene expression and expansion of CD1d-restricted invariant natural killer T (iNKT) cells. Whether tick exposure activates these T cell subpopulations to promote α-Gal-sIgE and dietary α-Gal-specific hypersensitivity responses remains unclear. We injected α-Gal-deficient (AGKO) mice on a C57BL/6J background with: (1) protein-rich Aa tick whole body extracts with or without anti-CD1d monoclonal antibody 19G11; (2) iNKT lipid activator α-galactosylceramide plus α-Gal glycoprotein (cetuximab) or (3) lipid-enriched Aa tick whole body extracts. We profiled circulating CD4+T and/or iNKT cell subsets and measured serum cytokines and α-Gal-specific and total IgE and IgG1. We infested AGKO mice with adult Aa ticks to determine if AGS-associated tick bites altered CD4+ T and iNKT populations. We measured serum mast cell mediators after oral challenge with α-Gal-containing beef thyroglobulin to assess dietary α-Gal-induced mast cell activation. Tick extract injections induced α-Gal sIgG1, expanded circulating Th2 cells, promoted systemic type 2 (T2)-skewed cytokine responses, and primed for dietary alpha-gal-induced mast cell activation in AGKO mice. Activating iNKT cells with alpha-galactosylceramide concurrent with cutaneous α-Gal-glycoprotein injections, or with lipid-enriched tick extracts alone, induced α-Gal-sIgE. Disrupting CD1d-iNKT cell interactions blunted T2 cytokine-producing iNKT cell expansion induced by tick lipids; α-Gal-sIgE production; and α-Gal-induced mast cell activation. Importantly, infesting with adult Aa ticks increased circulating activated iNKT and Th2 cell frequencies and systemic IL-4, α-Gal sIgG1, and sIgE levels, priming mast cells for degranulation after dietary α-Gal challenge. CD1d-iNKT cell interactions may enhance early T2 cytokine production induced by tick bite, supporting α-Gal sIgE production and amplifying α-gal-induced mast cell degranulation primed by tick-induced, systemic T2-skewing.

PMID 43049226
阅读全文 →
PubMedBMC oral health2026-11-17

Efficacy of radical resection following neoadjuvant targeted therapy combined with chemotherapy for locally advanced oral squamous cell carcinoma: a propensity score-matched retrospective cohort study.

Zhao Lin L, Zhang Aihua A, Li Menghan M, Chen Zhiqing Z et al.

This retrospective cohort study evaluated the impact of two cycles of cetuximab plus nab-paclitaxel and cisplatin (TPE) neoadjuvant therapy followed by radical resection, compared with upfront surgery (UFS), on 2-year survival outcomes in locally advanced oral squamous cell carcinoma (OSCC). Clinical data from 750 OSCC patients admitted between October 2022 and October 2025 were retrospectively analyzed. Propensity score matching (age, sex, primary tumor site) yielded 27 patients per group. Objective response rate (ORR), pathological complete response (pCR), and adverse reactions were assessed. Kaplan-Meier and multivariate Cox regression analyses evaluated survival outcomes. All 27 TPE patients completed two cycles. ORR was 59.26% (complete response [CR] 11.11%, partial response [PR] 48.15%, stable disease [SD] 40.74%; no progressive disease [PD] observed). pCR rate was 22.22%. Common adverse reactions included alopecia (100%) and rash (88.9%), all grade 1-3; no grade 4 events, treatment-related deaths, dose reductions, or surgical delays occurred. Two-year overall survival was 80.0% (TPE) vs. 73.1% (UFS) (P > 0.05); 2-year event-free survival was 74.8% vs. 66.7% (P > 0.05). Subgroup analysis showed significantly longer event-free survival in objective responders versus SD patients (P = 0.027). Multivariable Cox models showed neoadjuvant therapy did not reach significance for OS (P = 0.283) or EFS (P = 0.213). The TPE regimen demonstrated an acceptable safety profile in locally advanced OSCC. Patients achieving objective response may derive clinical benefit from TPE-based neoadjuvant therapy.

PMID 43040503
阅读全文 →
PubMedCancer treatment and research communications2026-11-14

Efficacy and safety of cetuximab or capecitabine monotherapy as maintenance therapy in RAS/BRAF Wild-type metastatic colorectal cancer: a retrospective study.

Yang Feng F, Yang Rong R, Chen Juan J, Chen Wenqi W et al.

For RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC), the optimal maintenance strategy following first-line cetuximab-based chemotherapy remains controversial. This retrospective study enrolled 162 patients who completed ≥8 cycles of first-line cetuximab combined with FOLFOX or FOLFIRI. Patients were stratified into cetuximab maintenance (n = 53), capecitabine maintenance (n = 27), and observation (n = 82) groups. The primary endpoint was progression-free survival (PFS). Median PFS was 5.4 months in the observation group, 12.0 months in the cetuximab maintenance group, and 9.2 months in the capecitabine maintenance group. Compared with observation, both maintenance strategies significantly reduced the risk of progression (cetuximab: HR = 0.514, P = 0.001; capecitabine: HR=0.541, P = 0.018), whereas no significant between-group difference was observed (HR = 0.971, P = 0.916). Maintenance therapy was an independent significant prognostic factor. Grade 1-2 skin reactions were unique to cetuximab, and grade 3-4 gastrointestinal adverse events were restricted to capecitabine. Overall adverse event rates were comparable, and no severe adverse events resulted in treatment discontinuation. Single-agent maintenance with cetuximab or capecitabine is associated with improved PFS versus observation after first-line cetuximab-based chemotherapy in patients with RAS/BRAF WT mCRC, with a favorable safety profile. No significant difference in PFS was identified between the two maintenance agents, though therapeutic equivalence cannot be confirmed given the limited sample size. Capecitabine provides a convenient oral alternative for long-term maintenance, which may facilitate individualized clinical decision-making.

PMID 43025264
阅读全文 →

注册免费账户还可查看另外 8783 篇文献

免费注册查看全部文献 →

了解更多cetuximab